Your browser is no longer supported. Please, upgrade your browser.
ENTA Enanta Pharmaceuticals, Inc. monthly Stock Chart
ENTA [NASD]
Enanta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own5.50% Shs Outstand20.07M Perf Week-2.83%
Market Cap862.29M Forward P/E- EPS next Y-5.71 Insider Trans0.00% Shs Float17.66M Perf Month-2.52%
Income-36.20M PEG- EPS next Q-0.81 Inst Own95.50% Short Float13.77% Perf Quarter-16.36%
Sales122.50M P/S7.04 EPS this Y-182.00% Inst Trans3.39% Short Ratio13.87 Perf Half Y-15.33%
Book/sh22.70 P/B1.89 EPS next Y-40.30% ROA-7.20% Target Price61.63 Perf Year-32.37%
Cash/sh19.23 P/C2.23 EPS next 5Y- ROE-7.60% 52W Range38.40 - 67.88 Perf YTD-30.56%
Dividend- P/FCF151.28 EPS past 5Y-19.60% ROI-9.40% 52W High-36.80% Beta0.55
Dividend %- Quick Ratio18.10 Sales past 5Y-5.30% Gross Margin- 52W Low11.72% ATR1.89
Employees141 Current Ratio18.10 Sales Q/Q-54.00% Oper. Margin-34.00% RSI (14)39.53 Volatility5.12% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-432.10% Profit Margin-29.50% Rel Volume0.47 Prev Close42.94
ShortableYes LT Debt/Eq0.00 EarningsNov 23 AMC Payout- Avg Volume175.40K Price42.90
Recom2.60 SMA20-4.20% SMA50-4.36% SMA200-12.60% Volume82,945 Change-0.09%
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Aug-26-20Initiated Piper Sandler Overweight $87
Jul-27-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $70
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Oct-23-15Downgrade Barclays Equal Weight → Underweight $45 → $16
Nov-25-20 12:10AM  
Nov-23-20 10:00PM  
05:35PM  
04:19PM  
04:01PM  
02:15PM  
Nov-20-20 10:03AM  
Nov-18-20 07:02AM  
Nov-16-20 07:02AM  
Nov-12-20 12:30PM  
Oct-27-20 09:54AM  
Oct-12-20 01:27PM  
Sep-28-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 07:01AM  
Aug-28-20 06:15AM  
Aug-26-20 09:42AM  
Aug-20-20 07:00AM  
Aug-07-20 09:28AM  
Aug-05-20 01:31AM  
Aug-04-20 06:35PM  
04:21PM  
04:01PM  
Aug-03-20 07:02AM  
Jul-28-20 12:32PM  
07:01AM  
Jul-17-20 01:41PM  
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
04:03PM  
04:03PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
12:33PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
04:00PM  
02:30PM  
Feb-05-20 04:11PM  
Feb-03-20 07:27AM  
Jan-30-20 12:31PM  
Jan-24-20 07:30AM  
Jan-14-20 05:30AM  
Jan-09-20 07:30AM  
Jan-04-20 08:44AM  
Dec-30-19 07:30AM  
Dec-11-19 11:25AM  
Dec-09-19 07:38AM  
Dec-07-19 11:24PM  
Nov-22-19 08:18AM  
Nov-21-19 05:15PM  
04:00PM  
07:22AM  
Nov-17-19 08:42AM  
Nov-14-19 10:30AM  
Nov-11-19 10:21AM  
07:30AM  
Nov-05-19 04:00PM  
Oct-27-19 10:29PM  
Oct-21-19 04:00PM  
Oct-12-19 10:03AM  
Oct-03-19 07:30AM  
Sep-30-19 04:48PM  
Sep-26-19 04:16PM  
11:40AM  
07:54AM  
Sep-25-19 04:28PM  
04:12PM  
04:00PM  
Sep-12-19 09:48AM  
Sep-10-19 07:30AM  
Aug-21-19 07:30AM  
Aug-19-19 02:54PM  
Aug-13-19 01:24PM  
Aug-07-19 12:37PM  
Aug-06-19 05:55PM  
04:00PM  
Aug-02-19 08:51AM  
Jul-30-19 10:38AM  
Jul-15-19 07:30AM  
Jul-11-19 09:00AM  
Jul-08-19 07:30AM  
Jun-14-19 02:06PM  
11:12AM  
09:51AM  
06:00AM  
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MELLETT PAUL JTreasurer and CFONov 11Option Exercise2.543,4808,84946,304Nov 12 04:12 PM
Gardiner Nathaniel S.Sr. VP & General CounselAug 05Option Exercise30.001,66649,98029,271Aug 06 04:38 PM
MELLETT PAUL JTreasurer and CFOMay 05Option Exercise1.211,7402,10042,824May 07 05:35 PM
Gardiner Nathaniel S.Sr. VP & General CounselMar 12Option Exercise30.003,00090,00027,605Mar 16 06:27 PM
MELLETT PAUL JTreasurer and CFOJan 02Sale60.8810,000608,80040,054Jan 06 06:17 PM